Full Press Release Details
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study.
IMMP
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study
Key Takeaway: Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study